Iterum Therapeutics plc (ITRM) Research

Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations. Sulopenem is currently undergoing advanced (Phase III) clinical evaluation for its potential in addressing uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. Established in 2015, Iterum Therapeutics maintains its corporate headquarters in Dublin, Ireland.

Market snapshot

Symbol
ITRM
Price
$0.03
Day change
-10.98%
Market cap
$1.9M
P/E ratio
-0.06x
52-week range
0.0271-1.42
Sector
Healthcare
Industry
Biotechnology

Recent news

  • Iterum files wind-up petition due to limited cash, inability to raise equity

    Iterum Therapeutics said on Friday it has filed a petition in Ireland's High Court to ​wind up the drugmaker and was placed ‌into provisional liquidation, with a hearing set for April 13.

Peer companies

  • AN2 Therapeutics, Inc. (ANTX)
  • Boundless Bio, Inc. (BOLD)
  • iBio, Inc. (IBIO)
  • Intensity Therapeutics, Inc. (INTS)
  • Klotho Neurosciences, Inc. (KLTO)
  • Pluri Inc. (PLUR)
  • Q32 Bio Inc. (QTTB)
  • Rallybio Corporation (RLYB)

Open Iterum Therapeutics plc (ITRM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.